Ginkgo Logo Lockup 1 White
zoom-logo
cell therapy services

Learn about Ginkgo's latest tech for cell therapy R&D, including recent data from our CAR screening platform.

We can help you discover novel CAR-T therapeutics, including candidates that may be effective against solid tumors.

79%

would definitely recommend

85%

say more engaging than average

95%

 rate useful

Speakers

Narendra Maheshri (1)

Narendra Maheshri

Vice President

Mammalian Engineering

Ph.D ChemEng UC Berkeley

shawdee (2)

Shawdee Eshghi

Senior Director

Mammalian Engineering

Ph.D BioE MIT

Ginkgo by the Numbers

R&D Capabilities

• $500 million in infrastructure

• 550+ scientists, automation engineers & data experts

• Largest user of synthetic DNA in the world (100k+ constructs per year)

Cell Therapy

• 10,000 unique CAR-T signaling combinations

• 700,000 functional CAR-T tests in one screening campaign

• 100,000,000 T-cell transductions

Our Recent Partners

ginkgopressrelease-2
final-edited_boeringer-ingelheim
final-edited_aldevron
edited-ginkgopressrelease-4

What You'll Learn

With Ginkgo's foundry, we generate massive libraries of unique CAR designs with different signaling domains.

These can then be screened in an assay that mimics a solid tumor environment.

We'll present head-to-head tests, highlighting improved performance compared to standard signaling domains.

Ginkgo's cell therapy capabilities extend beyond current CAR-T strategies, toward reprogramming any cell in any way.

Discover and optimize the next generation of cell therapies for the endpoints that matter to you.

Register to Learn More

Virtual Event: Cell Therapy Services

Wednesday, May 31

12:00pm - 1:00pm ET